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Inherited neuromuscular disorders aﬀect approximately one in 3,500 children. Structural muscular defects are most common;
however functional impairment of skeletal and cardiac muscle in both children and adults may be caused by inborn errors of
energy metabolism as well. Patients suﬀering from metabolic myopathies due to compromised energy metabolism may present
withexerciseintolerance,musclepain,reversibleorprogressivemuscleweakness,andmyoglobinuria.Inthisreview,thephysiology
ofenergymetabolisminmuscleisdescribed,followedbythepresentationofdistinctdisordersaﬀectingskeletalandcardiacmuscle:
glycogen storage diseases types III, V, VII, fatty acid oxidation defects, and respiratory chain defects (i.e., mitochondriopathies).
The diagnostic work-up and therapeutic options in these disorders are discussed.
1.Introduction
Both skeletal and heart muscle are highly dependent on
energy supply. As energy demand of these muscle tissues
varies by several orders of magnitude, energy metabolism
has to be tightly regulated in order to meet varying energy
requirement.
In this review, we shall ﬁrst describe the physiology of
energy metabolism in muscle, and then deal with diﬀerent
myopathies caused by inborn errors of energy metabolism.
2. Physiology of Energy MetabolisminMuscle
Glucose, fatty acids, and, to a lesser extent, amino acids
serve as energy substrates for skeletal muscle cells. During
quiescence, fatty acids are the main fuel. However, glucose
and 6 amino acids (leucine, isoleucine, valine, asparagine,
aspartate, glutamate) may also be used by the resting muscle
[1, 2]. Only leucine and isoleucine can be oxidised in muscle
after being converted to acetyl CoA. The other amino acids
are used solely for de novo synthesis of citric acid cycle-
intermediates.
Glycogen is stored in skeletal and heart muscle. In
contrast to liver glycogen, muscle glycogen does not serve
glucose homeostasis in the body but is almost exclusively
used for energy metabolism in muscle itself. In the initial
phase of exercise, blood supply to skeletal muscle is not yet
adequate; hence oxygen and blood-born energy substrates
(i.e., fatty acids) are lacking. In this early phase, muscle
relies on its own energy reserves, that is, muscle glycogen,
and generates energy via anaerobic pathways. After a few
minutes, blood vessels dilate, blood ﬂow rises, and muscle
cells are provided with oxygen and blood-born substrates.
During this phase of exercise, muscle relies on aerobic energy
generation via oxidative phosphorylation, mainly from fatty
acids, but also (to a lesser extent) glucose and amino
acids.
Fatty acids are metabolized in the mitochondrial matrix
to acetyl-CoA via beta-oxidation (Figures 1 and 2). Fatty
acids are the major source of energy in man, especially
during fasting. Most tissues are able to oxidize fatty acids to
CO2 and water. In addition, liver has the capacity to syn-
thesize ketone bodies (acetoacetate and 3-hydroxybutyrate
from acetyl-CoA), which serve as an important fuel for
extrahepatic organs, especially the brain, during catabolism.
A rate-limiting step in mitochondrial fatty acid oxida-
tion is the carnitine-palmitoyltransferase 1 (CPT1) reac-
tion [3]. Adequate glucose supply, conversion of acetyl-
CoA to malonyl-CoA by acetyl-CoA carboxylase, and the
concomitant inhibition of CPT1 reduce long-chain fatty2 Journal of Biomedicine and Biotechnology
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Figure 1: Mitochondrial biochemical pathways involved in energy production: including fatty acid oxidation, the respiratory chain, and
TCA-cycle (Krebs-cycle) CPT1: Carnitine-Palmitoyltransferase 1; CPT2: Carnitine-Palmitoyltransferase 2; CAT: Carnitine-/Acylcarnitine-
Transferase; LC: Long-chain; TCA: Tricarboxylic acid cycle.
acid uptake and oxidation (Figure 2). Although these eﬀects
have primarily been shown in liver and heart, there is
also evidence for a regulatory function of malonyl-CoA in
skeletal muscle [4]. Malonyl-CoA levels decrease when the
muscle is fuel-deprived or energy consumption is increased
during contraction. Long-chain fatty acids cannot freely
crosstheinnermitochondrialmembraneandareshuttledvia
the carnitine system; acyl-CoA molecules are ﬁrst coupled
to carnitine, catalysed by carnitine-palmitoyltransferase I
(CPT 1), and the acylcarnitine complex then crosses the
highly impermeable inner mitochondrial membrane. In the
mitochondrial matrix space, acylcarnitines are reconverted
to acyl-CoA via carnitine-palmitoyltransferase 2 (CPT2)
(Figure 1)andsubsequentlyenterbeta-oxidation[5].Acetyl-
CoA derived from beta-oxidation, amino acid-, or glucose-
metabolism is channelled into the citric acid cycle. In
the citric acid cycle, redox equivalents (FADH2, NADH)
are produced which are substrates of the mitochondrial
respiratory chain (Figures 1 and 2). Electrons released from
these redox equivalents enter the respiratory chain and are
ﬁnally transferred to oxygen. Electron transport is linked to
the build-up of an electrochemical proton gradient across
the inner mitochondrial membrane [6]. The electrochemical
gradientcanbeusedtosynthesizeATPviathemitochondrial
ATPsynthase(complexV)ordrivetransmembranetransport
processes directly.
Creatine is phosphorylated by creatinekinase to cre-
atinephosphate(CP)whichcanbeusedasan“energybuﬀer”
and is split to ATP via reversal of the creatinekinase-reaction.
CP-stores in muscle are only a short-term “energy buﬀer”
and are used-up within the ﬁrst 30 seconds of exercise.
As mentioned above, energy demand is highly variable
in muscle. Energy supply has to be commensurated with
energydemand;thereforeenergydemandishighlyregulated.
Calcium (which mediates mechanical muscle contraction)
serves as an important regulatory element of metabolism.
Regulation of energy metabolism can occur at several levels.
(1) The key enzyme in aerobic mitochondrial energy
production via oxidative phosphorylation is ATPsyn-
thase (complex V). Classically, it was believed that
ATPsynthase is regulated passively by its substrate
ADP; mechanical activation of muscle results in
breakdown of ATP to ADP, hence higher substrate
saturation of the ATPsynthase and increased ﬂux. We
and others have shown in various tissues that the
ATPsynthase is actively regulated [7–11], probably
via the calcium binding inhibitor protein (CaBI)
[12]. This regulatory protein dissociates from the
ATPsynthase in response to elevated intramitochon-
drial calcium concentration during contraction, thus
leading to desinhibition of the ATPsynthase, hence
higher ﬂux. In animal models, we have previously
shown that this regulation breaks down under diﬀer-
ent pathophysiological conditions [7, 8, 13–16].
(2) Similarly to ATPsynthase, enzymes of the citric acid
cycle have been shown to be upregulated in response
to increased intramitochondrial calcium levels [17,
18]. Thus, intramitochondrial concentrations of
redox equivalents (NADH, FADH2) as substrates
of the mitochondrial respiratory chain rise in con-
cert with the activity of mitochondrial ATPsynthase
(cf. 1).
(3) Pyruvatedehyrogenase occurs in a nonphosphory-
lated (active) and a phosphorylated (inactive) form.
It is regulated by calcium [19]: muscle contrac-
tion is accompanied by increased muscle calciumJournal of Biomedicine and Biotechnology 3
LC-fatty acids LC-Acyl CoA
CPT1
LC-Acyl carnitine CAC
Carnitine
Malonyl-CoA
Acetyl-CoA-carboxylase
Carnitine
LC-Acyl carnitine
Acyl-CoA
CPT2 β-oxidation
TCA
PDH
PC
Mitochondrial matrix
Citrate Citrate
Oxaloacetate
ATP-citrate-lyase
Pyruvate/lactate
Cytosol
Acetyl-CoA
Glucose-6-P
Acetyl-CoA
+
oxaloacetate
Figure 2: llustration of biochemical interactions: the carnitine shuttle, fatty acid oxidation, and glycolysis. The mitochondrial membrane is
not permeable to long-chain fatty acids. The carnitine shuttle has to be used to transfer long-chain fatty acids to the mitochondrial matrix
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concentrations which favours the nonphosphory-
lated form of pyruvatedehydrogenase by activating
pyruvatedehydrogenase-phosphorylase and inhibit-
ing kinase [20]. During exercise, muscle glycogenol-
ysis leads to increased production of pyruvate.
Pyruvate as the substrate of pyruvatedehydrogenase
may subsequently lead to higher substrate saturation,
hence higher ﬂux. However, this mechanism is only
of minor importance in human skeletal muscle in
vivo [20].
Nitric oxide (NO) and its derivatives inhibit mitochon-
drial respiration by a variety of means. NO can inhibit
mitochondrial cytochrome c-oxidase (complex IV) of the
respiratory chain by reversibly competing with oxygen for
the binding site. Higher concentrations of NO have been
shown to uncouple mitochondria, inhibit complex I, and
lead to permeability transition [21, 22]. Mitochondrial NO
synthase may be of particular importance in this context
as it is regulated by the mitochondrial membrane potential
with reduced membrane potential leading to NO synthase
inhibition [23, 24].
Specialized skeletal muscle ﬁbres exist: red muscle ﬁbres
are rich in mitochondria and are used for slow and long-
lasting contractions (endurance) while white muscle ﬁbres
predominantly rely on anaerobic glycolysis and can be found
in ‘fast and short twitch’ muscle.
Incontrasttoskeletalmuscle,energymetabolisminheart
muscle is almost exclusively aerobic under physiological
circumstances. Fatty acids are the main source of energy in
the heart: under normal conditions up to 70% of the energy
requirement of the heart is provided by fatty acid oxidation,
which may be even higher under certain conditions. The
regulatory elements described above for skeletal muscle are
operative in cardiac muscle as well.
3.Ge ne ralDiagnosticT oolsin
Metabolic Myopathies
Here we give a general overview of diagnostic procedures
which may be useful in the workup of metabolic myopathies.
Formorespeciﬁcmethodsthereaderisreferredtothespecial
disease section.
At the metabolite level, elevated lactate concentrations in
blood and/or urine may be a clue to impaired aerobic energy
metabolism (oxidative phosphorylation) and (compensato-
rily) increased rates of anaerobic glycolysis with lactate as
the end product (Pasteur-eﬀect). The lactate/pyruvate ratio
in blood reﬂects the cytosolic NADH/NAD-ratio and may
therefore be elevated when aerobic energy metabolism is
compromised (e.g., defects of respiratory chain enzymes).
The ketone-body ratio (β-hydroxybutyrate/acetoacetate,
βHOB/AcAc) reﬂects the intramitochondrial NADH/NAD-
ratio and may be elevated under certain conditions of4 Journal of Biomedicine and Biotechnology
compromised aerobic energy production (e.g., respiratory
chain defects) as well. Impaired oxidative phosphorylation
may also be accompanied by elevated excretion of citric
acid cycle intermediates (e.g., aconitate, succinate) which
can be determined by analysing organic acids in spot-urine.
Dicarboxylic acid excretion in urine is a metabolic hallmark
both of defects in mitochondrial fatty acid oxidation and
respiratory chain enzymes (leading to secondary inhibition
of fatty acid oxidation). This ﬁnding might also be the result
of a diet rich in medium chain triglycerides (MCT enriched
diet as used in preterm infants and cholestatic hepatopathy).
Acylcarnitine proﬁles measured from dried blood spots
using the tandem-mass spectrometry technique (tandem-
MS) may be indicative of fatty acid oxidation disorders. They
are now integrative part of the routine newborn screening
programme in many countries as a strategy of primary
prevention.
A lactate-ischaemia test may be indicated when glyco-
gen storage diseases of muscle are suspected. In healthy
individuals, forearm exercise leads to a rapid increase in
lactate levels, paralleled by an increase in blood ammonia
concentrations. In glycogen storage disease type V there
is no or only attenuated lactate elevation in response to
testing, while ammonia production is increased [25]. The
nonischaemic forearm exercise test has been found to be less
speciﬁcandsensitiveandisthereforenotrecommended[26].
For morphological studies of muscle, ultrasound scans,
MRI, and biopsy with subsequent histological work-up
(including staining) as well as electron microscopy can be
used. Traditionally, freeze clamping of percutaneous needle
biopsy material has been used to biochemically study muscle
energy metabolism. This method has limitations as far as
stability of biochemical compounds and repetitive sampling
in order to calculate kinetics are concerned.
31-phosphorous (31P) magnetic resonance spectroscopy
(MRS) is an elegant, noninvasive method to judge energy
metabolism in vivo [27]. Several peaks corresponding
to creatinephosphate (CP), inorganic phosphate, the 3
phosphate groups of ATP, and phosphomonesters can be
observed. Kinetic studies using this technique may reveal
delayed recovery of phosphocreatine [28, 29]. Recently, the
use of 13C-labeled substrates has been advocated to assess
mitochondrial metabolism [30].
Another noninvasive technique to assess metabolic func-
tion in muscle is positron emission tomography (PET) with
g l u c o s ea ss u b s t r a t e[ 31]. 18F-Deoxyglucose is commonly
used as a marker of glucose metabolism. By comparing
glucose metabolism after exercise with reference values,
abnormalities may be detected in patients with defects in
energy metabolism.
4.InbornErrorsof Energy
Metabolism inMuscle
4.1. Disturbance of Glycogen Metabolism
(Glycogen Storage Diseases)
4.1.1. General Aspects. In this section, we deal with defects of
glycogen metabolism. Glycogen storage disease type II—also
known as Pompe disease—can lead to dysfunction of skeletal
andcardiacmuscle.Asthisdiseaseinvolveslysosomalstorage
of glycogen but no abnormality in the biochemical pathways
leading to energy generation, we shall not deal with this
disease in detail. On the other hand, glycogen storage disease
type VII is caused by a defect in the glycolytic pathway,
with secondary storage of glycogen. As energy metabolism
is compromised in this disease we shall describe this entity in
detail below.
4.1.2. Glycogen Storage Disease Type III
(M. Cori-Forbes; Deﬁciency of Amylo-1,6-Glucosidase;
Debranching Enzyme)
Pathogenesis. Glycogen storage disease type III (GSD III;
OMIM232400)isalsoknownasCoridisease,Forbesdisease,
and limit dextrinosis. The symptoms associated with GSD
III were ﬁrst described in 1952 by Illingworth and Cori and
were studied clinically by Forbes, hence the eponyms for
this disorder. It is an autosomal recessive disease aﬀecting
glycogen metabolism. The overall incidence of this disease is
approximately 1:100,000 live births in the USA. However,
in other populations GSD III may occur with a higher
frequency; for example, in the Faroe Islands a prevalence of
1:3,600 has been estimated [32].
GSD III is caused by deﬁciency of the glycogen
debranching enzyme amylo-1,6-glucosidase, 4-alpha-
glucanotransferase (AGL). It degrades glycogen branches
releasing glucose in a two-step reaction. Debranching
enzyme has two independent catalytic activities: oligo-1,4-
1,4-glucantransferase and amylo-1,6-glucosidase, localised
in two distinct protein regions. Patients with debrancher
deﬁciency are classiﬁed into four types: IIIa: lack of both
glucosidase and transferase activity in liver and muscle;
IIIb: lack of both activities in liver only; IIIc: selective loss
of glucosidase activity; and IIId: selective loss of transferase
activity [33–35].
Most GSD III patients (about 85%) have AGL deﬁciency,
expressed in both liver and muscle (type IIIa), but some
only in liver but not muscle (type IIIb). Diﬀerences in
tissueexpressionofthedeﬁcientenzymehavebeendescribed
(immunoreactive material and enzyme activity) [34].
Debranching enzyme is encoded by the 85-kb AGL
gene on chromosome 1p21. Genetic screening led to the
observation that GSD IIIb patients had mutations in exon
3, whereas GSD IIIa patients had downstream mutations. To
date, no common mutation has been described among GSD
III patients, except for three alleles, two linked speciﬁcally
with GSD IIIb, and the third found only in North African
Jews with GSD IIIa.
Clinical Features. Clinically, patients with GSD III present
in infancy or early childhood with hepatomegaly, hypogly-
caemia, and growth retardation. Initially, the clinical picture
may be quite similar to GSD I, however biochemically lactate
and uric acid concentrations are usually normal in GSD III,
and ketone bodies can be found in hypoglycaemia. During
puberty and early adulthood, symptoms seem to regress
and most patients have only minimal signs of hepatopathyJournal of Biomedicine and Biotechnology 5
[36, 37]. There is, however, a risk for cirrhosis and in rare
cases even hepatocellular carcinoma may develop in the
long run [38]. Muscle weakness in those with GSD IIIa is
usuallyminimalinchildhoodbutcanbecomemoreseverein
adulthood; however the clinical course of myopathy is highly
variable [39, 40]. The cause of muscle damage is not clear.
Lactate—which could be used as an alternative fuel during
exercise—does not increase in GSD IIIa patients (David
Weinstein, personal communication) which may explain
muscle damage.
The predominant myopathic symptoms in adults are
distal weakness (aﬀecting mostly calves and peroneal mus-
cles) and proximal weakness of variable degree with a slow
disease progression [40]. Back pain and fatigue may be
present.Exercise-inducedmyoglobinuriaiscommonbeyond
childhood. Many patients show elevated serum creatine
kinase levels. Neuropathy may occur due to glycogen storage
in Schwann cells and axons which clinically manifests as
polyneuropathy [41].
Osteoporosis is another common symptom in GSD IIIa
aﬀectingnearly all patients. Its etiology is multifactorial [42].
Some patients have severe cardiac hypertrophy leading to
compromised heart function and even death. Also dilatative
cardiomyopathy of the left ventricle was described in anec-
dotal cases [43]. Heart disease may manifest as ventricular
tachycardia as well [44]. Most patients with GSD IIIa do not
develop symptoms of cardiomyopathy [45].
Diagnosis. For an accurate diagnosis, biochemical tests with
glycogen quantitation and determination of amylo-1,6-
glucosidaseactivityinaliverbiopsyspecimenorerythrocytes
are required. Mutation analysis of the AGL gene may be
helpful in some cases [46, 47] and has been advocated as a
screening test using a commercially available test kit [48].
In our opinion, primary screening by mutation analysis
is inappropriate. A molecular diagnostic scheme has been
proposed to diagnose GSD III noninvasively.
Most of the mutations (more than 30 are known) are
nonsense mutations caused by a nucleotide substitution
or small insertion or deletion. Some important genotype-
phenotypecorrelationshaveemerged.Inparticularaspeciﬁc
correlation of exon 3 mutations (17delAG and Q6X) with
GSD IIIb has been observed. Three other mutations seem
to have some phenotype correlation. Prenatal diagnosis is
possible at enzymatic and genetic level [46].
Therapy. Curative therapy is not available for debranching
enzyme deﬁciency. In order to avoid fasting hypoglycaemia
in infancy, dietary measures have been proposed. Frequent
daytime high protein feedings (45% carbohydrate, 25%
protein, 30% fat) and supplementation of uncooked corn
starch before sleep proved to be eﬀective in young patients
with regard to metabolic control (hypoglycaemia) and
growth retardation.
Eﬀects of dietary measures on myopathic symptoms in
adults are less well established even though there are reports
of improvement in patients following a high-protein diet. In
GSDIII,gluconeogenesisisintactandproteinmaybeusedas
a precursor for glucose. Over-treatment with cornstarch can
cause deposition of glycogen, which cannot be broken down,
leading to accumulation.
In patients with cardiomyopathy, symptomatic pharma-
cological treatment is mostly used. A diet providing 30% of
energy from protein and avoidance of over-treatment with
carbohydrate could be found to stabilize and even reverse
cardiomyopathy [49].
4.1.3. Glycogen Storage Disease Type V (McArdle Disease;
Deﬁciency of Muscle Phosphorylase)
Pathophysiology. Myophosphorylase activity is deﬁcient in
McArdle disease (OMIM 232600); the disorder is inherited
as an autosomal recessive trait. The myophosphorylase gene
is located on chromosome 11q13 and spans 20 exons [50].
T h em o s tc o m m o nm u t a t i o ni nN o rt h e r nE u r o p ea n dN o rt h
America is the nonsense mutation at R50X, previously
referred to as R49X [51, 52]. Genotype-phenotype corre-
lation is poor, modifying genes as angiotensin converting
enzyme or actin 3 genes may play a role [53–55].
As a consequence of myophosphorylase deﬁciency, the
contracting muscle is not able to mobilize adequate amounts
of muscle glycogen during the initial anaerobic phase of
exercise. This leads to an energy deﬁcit which cannot be
covered by creatinephosphate stores. During the aerobic
phase of exercise, blood-born substrates like fatty acids
and amino acids as well as glucose can be used as energy
substrates. However, the capacity of the tricarboxylic acid
cycle (TCA- or Krebs-cycle) is compromised as well. This
is due to the lack of pyruvate which is normally generated
from glucose via glycolysis and has an anaplerotic eﬀect
on the TCA-cycle via oxaloacetate. We could show adaptive
processes at the level of mitochondrial ATPsynthase in a
patient with McArdle disease (poster presentation at the 4th
World Muscle society Congress 1999: Das AM, Kohlsch¨ utter
A; Upregulation of mitochondrial respiratory chain enzymes
in GSD V).
Clinical Features. Symptoms typically begin in the second
to third decade of life. As ﬁrst reported by McArdle in
1951, patients typically suﬀer from exercise-induced muscle
pain, cramps, and fatigue [56]. These symptoms are most
pronounced during the ﬁrst few minutes of exercise (anaer-
obic phase) and may be accompanied by rhabdomyolysis
leading to myoglobinuria with burgundy discoloration of
urine. Acute renal failure secondary to myoglobinuria has
been reported in a few patients. After blood supply to the
exercising muscle has increased, symptoms disappear as
energy supply is reinstored; this phenomenon is known as
“second wind”. Most patients with McArdle disease learn
to cope with their problems by resting until muscle pain
subsides and resuming activity as soon as the aerobic
phase sets in (oxidizing fatty acids and other blood-born
substrates).
A less common manifestation of McArdle disease is
permanent muscle weakness. This kind of symptom usually
occurs later in life. Some patients may have proximal and
symmetric weakness while others have asymmetric weakness
mimicking facio-scapulohumeral dystrophy (FSHD) [57].6 Journal of Biomedicine and Biotechnology
Diagnosis. Plasma creatinekinase activity is usually elevated
at rest and rises in response to muscular activity. Patients fail
to produce lactate during the ischaemic forearm test while
ammonia concentration increases. Inosine, hypoxanthine,
and uric acid also increase reﬂecting accelerated recycling
of purine nucleotides in the face of insuﬃcient ATP-
production.
Muscle biopsy specimen usually shows subsarcolem-
mal and intermyoﬁbrillar vacuoles ﬁlled with glycogen.
Ultrastructurally, there are deposits of normal-looking free
glycogen particles and occasional alterations of sarcoplasmic
reticulum and mitochondria. Staining for phosphorylase is
negative in muscle ﬁbres whereas smooth muscle of blood
vessels stains normally.
Biochemically, reduced activity of phosphorylase may
be found by enzymatic assays. Diagnosis may be further
corroborated by mutation analysis (see above). This allows
deﬁnitive prenatal testing where appropriate.
Lack of lactate formation may lead to absent acid-
iﬁcation of myoplasm as judged by 31P-MRS [58]. The
phosphocreatine/ATP-ratio is usually elevated at rest, phos-
phocreatine depletion during exercise is larger than normal,
and recovery rate of phosphocreatine after exercise is slower
[58, 59]. Changes in T2-relaxation are often absent in
exercising muscle from McArdle patients [60]. EMG is
usually unrevealing between acute attacks.
Treatment. Both pharmacological and dietary interventions
have been tried in order to improve exercise intolerance.
Therapy of McArdle disease was subject of a recent Cochrane
review [61].24 studies werereviewed;12 of these fulﬁlledthe
criteria for inclusion. High protein, high carbohydrate, and
highfatdietsaswellasketogenicdiethavebeentriedwithout
signiﬁcant eﬀects. Furthermore, glucagon administration,
verapamil, ACE-inhibitors, sodium dantrolene, gentamicin,
vitamin B6, and creatine have been tested. Low-dose creatine
may have a modest beneﬁt in some patients [62] while
higher-doses may lead to deterioration [63]. All other
interventions did not have any beneﬁt. The Cochrane review
concludes that none of the tested pharmacological or dietary
interventions can be recommended.
4.1.4. Glycogen Storage Disease Type VII (Tarui Disease;
Deﬁciency of Muscle Phosphofructokinase)
Pathophysiology. Tarui disease (GSD VII; OMIM 232800) is
caused by deﬁciency of muscle phosphofructokinase. It is
inherited as an autosomal-recessive trait (gene map locus of
muscle phosphofructokinase PFKM 12q13.3).
Phosphofructokinase is a tetrameric enzyme derived
from 3 distinct genetic loci that code for muscle, liver, and
platelet isoforms. Mammalian PFK is a tetramer made up
of various combinations of 3 subunits: muscle (PFKM), liver
(PFKL), and platelet (PFKP), the genes for which are located
on chromosomes 12q13, 21q22, and 10p, respectively. The
composition of the tetramers diﬀers according to the tissue
t y p e .M u s c l ea n dl i v e rP F Ka r eh o m o t e t r a m e r so f4Ma n d
4L subunits, respectively. Erythrocytes contain both L and
M subunits.
The muscle phosphofructokinase gene is located on
chromosome12andabout20mutationshavebeendescribed
[64, 65]. Phosphofructokinase is not involved in glycogen
metabolism but is a glycolytic enzyme. The PFKM gene
encodes the muscle isoform of phosphofructokinase (PFK)
(ATP:D-fructose-6-phosphate-1-phosphotransferase). PFK
catalyzes the irreversible conversion of fructose-6-phosphate
to fructose-1,6-bisphosphate and is a key regulatory enzyme
in glycolysis.
Tarui disease has a relatively high prevalence in Japanese
people; in the western hemisphere it is prevalent in patients
of Jewish-Russian extraction.
Ifthemuscleisoenzymeofphosphofructokinase(PFKM)
is deﬁcient, not only is glycolysis in muscle aﬀected but
also glycolysis in erythrocytes is reduced to about 50%
(as the liver isoenzyme is fully active). As erythrocytes
have no mitochondria, this relatively mild reduction of
glycolytic ﬂux can critically reduce energy supply resulting in
haemolysis.
Clinical Features. Clinical symptoms are very similar to
McArdle disease with exercise-induced pain, muscle cramps,
and fatigue. As in McArdle disease the initial anaerobic
p h a s eo fe x e r c i s ei sa ﬀected when the muscle has to rely
on anaerobic glycolysis which is defective in Tarui disease.
The resulting energy shortage leads to the clinical symptoms
as ﬁrst described by Tarui et al. in 1965 [66]. There are
some features which may diﬀerentiate McArdle disease
from Tarui disease: in Tarui disease, symptoms are more
severe and often already present during childhood, often
accompaniedbynauseaandvomitingaswellascompensated
haemolytic anaemia, hyperuricaemia, and an abnormal
polysaccharide which is periodic acid-Schiﬀ positive. This
polysaccharide has a ﬁne ﬁbrillar appearance resembling
amylopectine.
After carbohydrate-rich meals, exercise intolerance is
often exacerbated. The pathophysiological basis for this
observation is probably the inability of muscle to use
glucose (anaerobically and aerobically) on one hand and
hyperinsulinism caused by hyperglycaemia with subsequent
lowering of fatty acids as energy substrates for muscle on the
other hand.
As in McArdle disease, there are variant forms of the
disease. One variant leads to muscle weakness in later adult
life while the other leads to hypotonia during infancy with
subsequent progressive myopathy leading to early death in
younger children.
Diagnosis. As in glycogen storage disease type V the
ischaemic forearm test has a pathologic result with insuﬃ-
cient lactate production accompanied by a rise in ammonia
levels.
Histochemical and biochemical demonstration of the
enzyme defect proves the suspected diagnosis. Mutation
analysis may be added for further conﬁrmation.
31P-MRS shows increased phosphocreatine/ATP ratio in
resting muscle, ATP depletion, larger than normal phospho-
creatine depletion during exercise with slow recovery rate
and absence of myoplasmic acidiﬁcation [67, 68].Journal of Biomedicine and Biotechnology 7
Therapy. There is no speciﬁc therapy for this condition.
Most patients try to avoid strenuous exercise, by slowing
down speed or pausing after onset of symptoms. Pain and
fatigue can be reduced, after adequate blood (and fatty acid)
supply sets in. Physical activity may be resumed without
problems after a short break.
4.2. Disturbance of Fatty Acid Oxidation
4.2.1. General Aspects
GeneralAspectsofPathophysiologyinFAODisorders(FAODs).
Mitochondrial fatty acid oxidation represents an important
pathway for energy supply in skeletal muscle during both
quiescence and periods of physical exercise. Cardiac muscle
preferentially oxidizes fatty acids for energy generation and
may have a limited ability to rely completely on glucose
during periods of stress [4, 69].
Among metabolic myopathies, long-chain mitochon-
drial fatty acid oxidation defects (FAODs) are probably
the most diﬃcult to identify due to the episodic charac-
ter of clinical and biochemical abnormalities which may
completely disappear during anabolism. The pathway of
fatty acid beta-oxidation includes at least 25 enzymes
and speciﬁc transport proteins. Deﬁciencies in more than
50 percent of these enzymes are known to cause dis-
ease in humans. Apart from overall energy deﬁcit in
the muscle toxic (lipophilic) compounds resulting from
compromised fatty acid oxidation, such as long-chain-
acylcarnitines,CoA-esters,ortheirfreelong-chainfattyacids
may play a role in the pathogenesis of clinical manifesta-
tions.
In this section we will focus on the following more
common disorders: Carnitinepalmitoyltransferase 2 (CPT2),
mitochondrial trifunctional protein (MTP), very-long-
chain-acyl-CoA dehydrogenase (VLCAD), multiple acyl-
CoA (MAD), as well as primary carnitine/carnitine trans-
porter-deﬁciency (CTD).
General Clinical Aspects of Long-Chain FAOD. In disorders
of long-chain fatty acid oxidation, clinical symptoms are
usually triggered by common infections, prolonged exercise,
and exposure to cold and prolonged fasting (catabolism).
In long-chain FAOD, the phenotype ranges from benign
forms with isolated skeletal muscle involvement to severe
phenotypes leading to early death as has been initially
described in patients with carnitine palmitoyltransferase 2
(CPT2) deﬁciency [70–72].
Newborns and infants commonly present with a mul-
tisystemic manifestation (including liver, muscle, and brain
involvement) often triggered by physiological catabolism
soon after birth, whereas onset later in life usually presents
with exercise intolerance, muscle weakness, and sometimes
myoglobinuria during metabolic decompensation. Myo-
globinuria may result in acute renal failure if ﬂuid intake is
restricted. Long-chain FAOD-associated myopathies of the
more chronic type manifest predominately during aerobic
endurance-type activity or under metabolically stressful
conditions. In contrast to patients with glycogen storage
diseases of muscle, patients suﬀering from FAOD do not
experience a “second-wind” phenomenon.
General Diagnostic Procedures in FAOD. The diagnosis is
based on detecting the accumulation of speciﬁc biochemical
markers such as acylcarnitine metabolites in blood, dicar-
boxylic acids, and acylglycines in urine by routine newborn-
or selective screening.
Medium- and long-chain fatty acid oxidation defects
have been included in the routine neonatal screening pro-
gram, for example, by the German screening commission.
Newborn screening for FAOD promises to identify many
aﬀected patients before the onset of symptoms or in the
early phase of metabolic decompensation. Physiological
catabolism in the ﬁrst days of life is helpful in demasking
biochemical abnormalities at metabolite level. Conﬁrmation
ofsuspectedmitochondrialfattyacidoxidationdefectsbased
on an initial abnormal newborn- or selective metabolic-
screening by tandem mass spectrometry should include
enzymeandwheneverpossiblemolecularanalyses.Biochem-
ical testing of urine (organic acids) may be unrevealing.
Patients who are not aware of their defect could be easily at
risk of decompensation when exposed to diﬀerent triggers,
that is, prolonged fasting, fever, or strenuous physical
exercise. Therefore, neonates (and older patients) suspected
to suﬀer from an FAOD should receive special monitoring
and follow an emergency regime until the metabolic defect is
excluded.
Pathologic ﬁndings in muscle biopsies are most often
nonspeciﬁc. Moderate lipid storage is present in only some
cases.
Of particular importance is the possibility of secondary
respiratory chain dysfunction in patients with FAO defects
or vice versa [73].
Diagnostic procedures in long-chain FAO disorders have
recentlybeensummarizedbasedontheresultsofaconsensus
workshop [74].
Speciﬁc diagnostic options are mentioned in more detail
below, where appropriate.
GeneralTreatmentPrinciplesofFAOD. Evidence-basedtreat-
ment recommendations for long-chain FAO defects are
not available [75]. However, at national/multinational levels
consensus protocols exist [76]. Current management of
patients with long chain fatty acid oxidation defects includes
long-termdietarytherapyincludingavoidanceoffasting,low
fat diet with the restriction of long-chain fatty acid intake,
and substitution with medium chain fatty acids. The long-
term outcome of patients treated by dietary modiﬁcation
remainsunknown[74,76].Dietarylong-chainfatrestriction
depends on the severity of the underlying enzyme defect.
Episodic muscular symptoms such as rhabdomyolysis
are pathogenetically attributed to energy deﬁciency, and
symptoms are reversed or may be prevented by suﬃcient
energy supply in the form of carbohydrates or MCT [77].
The incidence of overweight and obesity is increasing among
children with long-chain FAOD. A diet higher in protein and
lower in carbohydrate may help to lower total energy intake
while maintaining good metabolic control [78].8 Journal of Biomedicine and Biotechnology
In the past, supplementation with carnitine was pro-
posed in fatty acid oxidation defects for detoxiﬁcation of
accumulating long-chain acyl-CoA esters. Actually, carnitine
supplementation in long-chain FAOD is not recommended
[74].
Further therapeutic options have anecdotally been de-
scribed in single cases: Triheptanoin (seven-carbon medium
chain fatty acid) supplementation could show an improve-
mentofcardiacandmuscularsymptomsinpatientssuﬀering
from long-chain fatty acid oxidation disorders [79]. PPAR-
alpha agonists (like ﬁbrates) stimulated mitochondrial fatty
acid oxidation in vivo in both liver and muscle and
might be a therapeutic option in inborn errors of FAO
[80–82].
D,L-3-hydroxybutyrate could be a therapeutic option for
cerebral and cardiac complications in severe FAO [83].
Disease-speciﬁc therapeutic options are discussed below.
4.2.2. Carnitine Palmitoyltransferase 2 (CPT2) Deﬁciency
Pathophysiology. CPT2 is located at the inner aspect of the
inner mitochondrial membrane catalyzing the conversion
of long-chain acyl-carnitines to acyl-CoA esters. CPT2
deﬁciency (OMIM 600650) is inherited as an autosomal
recessive trait resulting in the accumulation of long-chain
acylcarnitines. The gene is located on chromosome 1p32
[84]. There are three phenotypes of CPT2 deﬁciency: the
“classic muscular form” (OMIM 255110) is most frequent
and shows onset in childhood or adulthood with exercise-
induced muscle weakness and rhabdomyolysis. CK levels
are found to be elevated during symptomatic periods, and
carnitine levels are usually normal [70]. The prevalent
c.338C>T (p.Ser113Leu) mutation is found in about 60%–
75% of mutant alleles [85]. This CPT2 mutation is ther-
molabile resulting in the degradation of the protein during
fever or muscular exercise accompanied by elevated body
temperature [86].
Clinical Features. A “severe neonatal form” (OMIM 608836)
presents in the newborn period with nonketotic hypo-
glycemia, cardiomyopathy, muscle weakness, and renal dys-
genesis in some patients [87]. Most of these patients die
within days after birth [88]. The “infantile multisystemic
phenotype” (OMIM 600649) is often fatal in the period
from 3 to 18 months of age. It presents with seizures,
hepatomegaly, nonketotic hypoglycemia, cardiomyopathy,
andmuscleweakness.Plasmafreecarnitinelevelsarelowand
long-chain acylcarnitines high [89]. These diﬀerent clinical
presentations appear to be correlated with diﬀerent residual
CPT2- and overall long-chain FAO-capacity [90].
Muscle CPT2 deﬁciency clinically manifests in patients
harboring only a single heterozygous mutation [91]. Com-
pound heterozygosity for a mild and a severe mutation can
beassociatedwitheitherthemildmuscleortheseveremulti-
systemic infantile form [92] .S e v e r a lh o m o z y g o u sm u t a t i o n s
have been reported, associated with either a prominent
skeletal muscle involvement or with a severe generalized
phenotype [93, 94]. Severe and intermediate phenotypes
were found to correlate with biochemical indices and
geneticanalysis.Milderphenotypessuggestlittleevidencefor
genotype-phenotype correlation [86].
The presence of only one severe mutation (the other
being a milder one) in a CPT2 deﬁcient patient might be
suﬃcient to lead to life-threatening events [92]. Severely
compromised long-chain fatty acid oxidation may point to
am o r es e v e r ec o u r s e[ 90, 95].
4.2.3. The Mitochondrial Trifunctional Protein
(MTP) Deﬁciency
Pathophysiology. MTP is an enzyme complex involved in the
beta-oxidation of fatty acids with chain lengths of C12 to
C18. It catalyzes three reactions in the oxidation of long
chain fatty acids and consists of the following enzymes:
3-hydroxyacyl-CoA dehydrogenase (LCHAD), 2-enoyl-CoA
hydratase, and 3-ketoacyl-CoA thiolase.
MTP is a hetero-octamer of 4 alpha- (OMIM 600890;
with LCHAD and 2-enoyl-CoA hydratase activities) and 4
beta-subunits (OMIM 143450; with 3-ketoacyl-CoA thiolase
activity). The alpha- and beta-subunits are encoded by
diﬀerent nuclear genes, consisting of 20 and 16 exons,
respectively. Both are located on chromosome 2p23 [96].
A deﬁciency in this heteromeric complex (OMIM
609015) was ﬁrst described in 1992 [97]. In contrast to
the large number of isolated LCHAD-deﬁcient patients
(OMIM 609016), only few MTP alpha- and beta-subunit-
deﬁcient patients were published [98]. Molecular studies
in MTP-deﬁcient patients show a wide range of “pri-
vate” mutations in both the alpha- and beta-subunit, in
contrast to the common 1528 G>C mutation (E474Q)
in LCHAD deﬁciency. Thiolase expression levels and the
diﬀerent rates of thiolase degradation as a result of
either alpha- or beta-subunit mutations were found to
correlate well with the severity of clinical manifestations
[96].
The biochemical hallmarks of this disorder are the
accumulationoflong-chain3-hydroxyacylcarnitinesandfree
fatty acids in blood as well as dicarboxylic acids in urine.
Clinical Features. These long-chain FAO defects have vari-
able presentations. They may present in the neonate or
infant with sudden death, hepatopathy (Reye-like dis-
ease), hypoketotic hypoglycaemia, rhabdomyolysis, myopa-
thy, cardiomyopathy, and capillary leak syndrome often
associated with lung oedema. Late complications such
as peripheral neuropathy, pigmentary retinopathy, retinal
degeneration, and progressive visual loss occur [97–100].
The clinical spectrum in MTP-deﬁciency seems to be
broader than in isolated LCHAD-deﬁciency, usually with
a ﬁrst manifestation earlier in life with a lethal out-
come.
Three phenotypes have been reported in patients with
alpha- or beta-subunit mutations: a “lethal form” with
predominating cardiac involvement, an “infancy-onset” hep-
atic presentation, and a milder “late-onset” neuromyopathic
form [96]. The main features of the neuromyopathic form
with late-onset are progressive peripheral neuropathy and
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4.2.4. Very Long-Chain Acyl-CoA Dehydrogenase
(VLCAD) Deﬁciency
Pathophysiology. VLCAD is bound to the inner mitochon-
drial membrane and catalyses the ﬁrst step of the long-chain
fatty acid beta oxidation spiral [101]. VLCAD deﬁciency
(OMIM 201475) is inherited as an autosomal recessive trait
(gene map locus 17p13).
Clinical Features. According to the age of onset, three phe-
n o t y p e sh a v eb e e nd e s c r i b e d[ 102–105]: a severe “infantile
form” presenting in the neonatal period with hypertrophic
cardiomyopathy and liver failure, a “childhood-onset” type
with hypoketotic hypoglycaemia, and a “juvenile or adult-
onset” muscular form characterized by recurrent episodes
of rhabdomyolysis triggered by prolonged exercise or fasting
(similar to CPT2 deﬁciency).
A clear genotype-phenotype correlation could be found
[102]: patients with the severe childhood phenotype have
mutations that result in absence of enzyme activity, whereas
patients with the milder childhood and adult (myopathic)
phenotypes have mutations that result in residual enzyme
activity. However, a recent report of life-threatening disease
with cardiomyopathy and hypoketotic hypoglycaemia in
a previously healthy 32-year-old woman underscores the
potential risk of severe complications, even in adults [106].
The milder form of VLCAD deﬁciency is increasingly
recognised due to the more wide-spread use of tandem mass
spectrometry, allowing the (presymptomatic) detection of
abnormal long-chain acylcarnitines in blood samples during
neonatal screening [107]. Some neonates show biochemical
abnormalities in routine screening but do not suﬀer from
clinical disease. For this, the term “Non-disease” (which is
poorly deﬁned as a condition where late-onset disease is
possible) has been coined. Clinical observation of patients
with late-onset presentation of VLCAD deﬁciency is scarce
[106, 108–117].
4.2.5. Multiple Acyl-CoA Dehydrogenase Deﬁciency
(MADD; Also Glutaric Aciduria Type II, GA II)
Pathophysiology. This is an autosomal recessively inherited
disorder of fatty acid, amino acid, and choline metabolism.
In multiple acyl-CoA dehydrogenase deﬁciency (MADD,
OMIM 231680) large excretion not only of glutaric acid but
also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-
butyric, and isovaleric acids in urine occurs. MADD results
from deﬁciency of one of three molecules: the alpha (ETFA)
and beta (ETFB) subunits of electron transfer ﬂavoprotein
(ETF), and electron transfer ﬂavoprotein dehydrogenase
(ETFDH), gene map locus 15q23-q25, 19q13.3, and 4q32-
qter.
Clinical Features. The clinical picture of MADD due to
the diﬀerent defects appears to be similar. The most
severely aﬀected patients have congenital anomalies and
die in the newborn period; other patients have hypogly-
caemia, encephalopathy, muscle weakness, or cardiomyopa-
thy. Mildly aﬀected patients present with muscle weakness
only [118]. Some patients present with respiratory dysfunc-
tion [119]. Each of the single enzyme defects can lead to a
mild or severe course, depending presumably on the location
and nature of the intragenic lesion. Therefore, mutations can
result in dysfunction of electron transfer ﬂavoprotein (ETF)
or ETF-ubiquinone oxidoreductase (ETF-QO). It results
in secondary deﬁciencies of a variety of FAD-dependent
enzymes, including glutaryl-CoA dehydrogenase, as well as
acyl-CoA dehydrogenases from FAO and branched-chain
amino acid metabolism [120].
Mutations in ETFDH, encoding ETF-QO, have been
associated with both riboﬂavin-responsive and nonrespon-
siveMADDaswellasamyopathicformofCoQ10deﬁciency
[121]. Pathomechanisms responsible for these diﬀerent
phenotypes are not well deﬁned [122, 123]. As with VLCAD
deﬁciency, there is a relationship between ETF/ETFDH
genotype and phenotype in patients with MADD.
In MADD early diagnosis is essential as some patients
respond to pharmacological doses of riboﬂavin. It has
recently been shown that rapid diagnosis of MADD via
newborn screening using tandem-MS is possible. Only in
some of these children, disease causing mutations could
be found; some were responsive to riboﬂavin even without
am u t a t i o n( p r e s e n t e da sa na b s t r a c ta t1 1 t hI C I E M -
congress in San Diego, 2009: Olsen et al. Multiple AcylCoA
Dehydrogenation Deﬁciency). Furthermore, coenzyme Q10
concentrations should be determined in patients suﬀering
from riboﬂavin responsive MADD.
Therapeutic Options in MADD. The eﬀect of riboﬂavin and
coenzyme Q10 should be tested [121]. Ketone bodies like D,
L-3-hydroxybutyrate are discussed as a therapeutic option
[83].
4.2.6. Systemic Primary Carnitine Deﬁciency/Carnitine
Transporter Deﬁciency (CTD)
Pathophysiology of CTD. Carnitine is ubiquitous in nature,
especially high in muscle tissue of higher organisms, but
low in vegetables. In humans, biosynthesis takes place in
liver and kidney. To fulﬁl its function, intracellular carnitine
concentrations have to be rather high, especially in skeletal
muscle cells. Therefore, active carnitine transport mecha-
nisms from blood into the cell have to exist. Translocation
is mediated by the carnitine transporter, a special protein,
which is located in cell membranes. The active transport
of carnitine into tissue takes place against a concentration
gradient,permittingtissuecarnitineconcentrationstobe20-
to 50-fold higher than plasma levels [124]. Furthermore, this
carnitine transporter reabsorbs all carnitine from primary
urine into blood. The sequence of the 557 amino acids of the
carnitine transporter is encoded on chromosome 5q31.2-32.
In case of carnitine transporter deﬁciency (OMIM
212120)—inherited as an autosomal recessive trait—
carnitine is lost in considerable amounts via urine; the body
becomes depleted of carnitine. As a consequence, impaired
oxidation of long chain fatty acids leads to deﬁcient energy
generation as well as reduced ketogenesis during fasting, and
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Clinical Features of CTD. Diﬀerent courses of CTD are
known. The most severe presentation can lead to sudden
infant death syndrome (SIDS) already in the neonatal
period [126]. Mean age of presentation with “Reye-like”
manifestations as hypoketotic hypoglycemic encephalopathy
is between one month and a maximum of 5 years with an
e s t i m a t e dm e d i a no f1 . 5y e a r s[ 127].
The metabolic deterioration is usually triggered by
prolonged fasting, reduced oral intake, or vomiting during
viral illness. Those who survive critical illness suﬀer from
recurrent episodes of encephalopathy if the defect is not
diagnosed and no carnitine supplementation is given [128].
Later in life, the disorder can present with skeletal muscle
disease causing muscular hypotonia with mild motor delay.
Progressive cardiomyopathy in late infancy or early
childhood (usually between 1 and 7 years of age, median
3 years) leads to dilatative cardiomyopathy with greatly
reduced left ventricular ejection fraction, abnormal T-waves,
and signs of ventricular hypertrophy [128, 129]. Bradycardia
and atrial arrhythmias are possible [130]. Sometimes no
overtcardiomyopathy,butonlymildinterventricularseptum
hypertrophy, does occur [130]. If no carnitine replacement is
given, progressive congestive heart failure may lead to death.
Another form of cardiac deterioration was ﬁrst described in
2004. A 15-year-old girl was diagnosed with cardiac arrest
due to ventricular ﬁbrillation without overt cardiomyopathy.
ECG showed nonsustained ventricular tachycardia with
periods of sinus rhythm and ventricular premature beats,
while echocardiography revealed normal left ventricular
dimensions and a borderline left ventricular hypertrophy
with good contractility [131].
Nicola Longo (personal communication) stated that
many of the patients who die suddenly with primary
carnitine deﬁciency do not have cardiomyopathy (beyond
childhood), but “only” sudden arrhythmias. The mechanism
causing the arrhythmias is subject to ongoing studies. Adult-
onset lipid storage myopathy presenting with myalgia and
muscular fatigue during prolonged exercise could be shown
to be caused by primary carnitine deﬁciency. Symptoms and
abnormalitiesinmusclebiopsyimprovedtremendouslyafter
four months of oral therapy with carnitine supplementation
[132].
Asymptomatic courses are known as well: Spiekerkoetter
et al. reported a 28-year-old man diagnosed with CTD, based
on a positive family history with disease manifestation in
one of his sons [133]. Four asymptomatic mothers were
discovered to have CTD when being examined for low
carnitine found by neonatal screening in blood spots of their
oﬀspring [134].
Patients with identical mutations can have diﬀerent age
of onset and diﬀerent type of clinical presentation [135].
Frequency of the diﬀerent courses is unknown. Many of the
adults dying from ventricular ﬁbrillation may have suﬀered
from undiagnosed CTD. We are aware of at least 4 young
adults from the Faroe Islands who showed this course
(unpublished data).
Diagnostic Options in CTD. Laboratory hallmarks of CTD
areverylowfreeplasmacarnitineconcentrations(lowerthan
10μmol/L) and increased fractional excretion of carnitine in
urine. During decompensation, glucose and ketone bodies
are inappropriately low. Transaminases and ammonia may
be moderately elevated, and metabolic acidosis, prolonged
prothrombin time, and elevated CK do occur.
Final conﬁrmation of the diagnosis can be done by
showing low activity of the transporter with decreased
carnitine uptake in ﬁbroblasts. Mutation analysis can be
performed.
Therapeutic Options in CTD. The treatment of CTD is easy
and without severe adverse reaction apart from a strange
“ﬁsh-like” body odour. Carnitine is supplemented in a dose
of 50–200mg per kg body weight and day given in at least
three portions.
4.3. Disturbance of Respiratory Chain Function
Pathophysiology. The respiratory chain is responsible for the
aerobic energy generation from diﬀerent substrates like fatty
acids, glucose, and amino acids. It is integrated in the inner
mitochondrial membrane which is almost impermeable.
ElectronsfromthereductionequivalentsNADHandFADH2
enter the respiratory chain via complex I and complex II,
respectively. Electrons then follow a potential gradient and
are ﬁnally transferred to oxygen. Flow of electrons leads
to the generation of an electrochemical proton gradient
across the inner mitochondrial membrane as protons are
pumped out of the mitochondrial matrix [6]. This gradient
can be directly used, for example, for the transport of
charged substances (e.g., ATP-ADP exchange). On the other
hand it can be used to drive the ATPsynthase (complex V)
reactionwhichdissipatestheprotongradientacrosstheinner
mitochondrial membrane. The mitochondrial ATPsynthase
has been shown to be actively regulated both in heart [136]
and in skeletal muscle [137].
The mitochondrial genome consists of 16,569 base pairs
(http://www.mitomap.org/MITOMAP). Mitochondria have
their own mitochondrial DNA. Some 80 mitochondrial
proteins are present in the mitochondrium, 13 of these are
encoded on the mitochondrial DNA. Some subunits from
complexes I, III, IV, and V are encoded on the mitochondrial
DNA while other subunits from complexes I–V are nuclear-
encoded. As mitochondrial DNA is inherited from the
mother, respiratory chain defects due to mutations in the
mitochondrialDNAfollowamaternalpatternofinheritance.
Mitochondrial DNA encodes both tRNA involved in pro-
tein synthesis and genes responsible for the generation of
subunits of respiratory chain complexes. Nuclear-encoded
mutations are inherited as an autosomal-recessive trait.
Most of the cells contain several mitochondria; each
mitochondrium harbours up to 10 copies of mitochon-
drial DNA. Mutations in mitochondrial DNA normally
do not aﬀect all DNA of one cell and not all cells of
one organ but there is a mixture of healthy and diseased
cells (heteroplasmy). The relative distribution between both
subsets can vary during life; the course of changes is
unpredictable. Deleted DNA may replicate faster due to
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Once a threshold is reached, clinical symptoms develop
(depending on the organ involved). This also explains the
high variability of clinical symptoms and lack of genotype-
phenotype correlation. Highly specialized cells, like mature
erythrocytes, do not contain mitochondria and are therefore
spared from mitochondrial dysfunction; however immature
forms of these cells may be aﬀected.
Mitochondrial dysfunction leads to a lack of energy in
aerobic tissues and production of possibly toxic free radicals
whichﬁnallymayinduceapoptosis[138,139].Mitochondria
are not only responsible for energy generation, but are able
to take up and release calcium, thus regulating calcium
homeostasis. This mitochondrial function is partly lost in
respiratory chain defects.
Clinical Features. Based on the central role of energy gen-
eration within cells, almost all organs may be aﬀected by
respiratory chain disorders. Cellular heteroplasmy leads to a
highly variable clinical picture of a single mutation. Organs
showing a high rate of aerobic energy metabolism are often
compromised ﬁrst by respiratory chain disorders. Skeletal
and heart muscle are frequently aﬀected.
The ﬁrst description of a mitochondrial myopathy was
by Luft et al. [140], in a patient with increased thermogenesis
in response to muscle exercise and ultrastructural abnormal-
ities of mitochondria. This patient presumably had “loose
coupling” between mitochondrial ATP production on one
hand and ﬂux of electrons across the respiratory chain on
the other hand [141]. In the late 1980s and early 1990s,
more and more patients with mitochondriopathies due to
mitochondrial dysfunction were reported.
Skeletal muscle dysfunction mostly presents as exercise
intolerance; rarely pain is reported. There may be either
isolated myopathy or a more complex disease with multisys-
temic manifestations.
Cardiac manifestations are limited exercise capacity,
overt heart failure in later stages accompanied by lung
oedema and hypertrophic cardiomyopathy; sometimes
arrhythmias are the dominating feature. Echocardiography
shows heart hypertrophy, sometimes dilatative cardiomy-
opathy, decreased shortening fraction, and often diastolic
dysfunction. The latter is caused by incomplete (energy-
dependent) uptake of calcium from the cytosol to the
sarcoplasmic reticulum and mitochondria. The ECG may
occasionally resemble infarction as this is also accompanied
by energy depletion (in the case of infarction due to lack of
oxygen).
Frequently, other organs are compromised by mitochon-
driopathyandnonmuscularfeatureslikeepilepsy,stroke,and
so forth, may predominate. Certain combinations of clinical
symptoms have been summarized as syndromes. The terms
Kearns-Sayre syndrome, mitochondrial encephalopathy, lac-
tic acidosis, and stroke-like episodes (MELASs), as well as
Leber’s hereditary optic neuropathy (LHON) were coined
and shown to be due to mutations in the mitochondrial
DNA. However, this is rarely helpful in the diagnosis or
treatment due to the large variability of clinical symptoms
in one single mutation.
Diagnosis. Creatinekinase (CK) activity may often be ele-
vated in plasma as an unspeciﬁc ﬁnding. Lactate con-
centration in blood—reﬂecting a compensatory increase
in ﬂux of anaerobic glycolysis—may be elevated (normal:
<2.6mmol/L). Lactate/pyruvate ratio reﬂects cytoplasmic
NADH/NAD ratio and may be increased (normal: less than
20) in defects of respiratory chain complexes I–V. However,
if only single organs are aﬀected, lactate levels as well as
lactate/pyruvate ratio in blood may be normal. Diagnostic
accuracy of the lactate/pyruvate ratio in blood has been
shown to increase with higher lactate concentrations [142].
In response to oral carbohydrates, lactate concentration in
blood may rise inappropriately in respiratory chain disor-
ders. If cytosolic NADH/NAD levels remain normal as in
pyruvatedehydrogenase deﬁciency, lactate/pyruvate ratio in
blood is normal. As many metabolic pathways have an eﬀect
on lactate and pyruvate metabolism, lactate/pyruvate ratios
may easily ﬂuctuate and may be unreliable. If determined
in tissue cultures the reliability of the lactate/pyruvate
ratio increases [143, 144]). The ketone body ratio (β-
hydroxybutyrate/acetoacetate) reﬂects the intramitochon-
drial NADH/NAD ratio and may be increased in respiratory
chain defects. Alanine may be elevated in blood.
In urine, increased amounts of lactate, pyruvate, and
ketone bodies may be found. Dicarboxylic aciduria reﬂecting
secondary inhibition of fatty acid oxidation (by accumu-
lating NADH and FADH) may be observed. Ethylmalonic
acid and 3-methylglutaconic acid excretion provide indirect
evidence for mitochondrial dysfunction.
Muscle biopsy is an important diagnostic tool. The
number of type I muscle ﬁbres (red) may be compensatorily
elevated. “Ragged red” ﬁbres—seen on a modiﬁed Gomorri
trichrome stain—are the hallmark of mitochondrial disease,
however these are not obligatory. Mitochondrial prolifera-
tion may also become evident using the succinate dehydro-
genase and cytochrome oxidase stains. The classic electron
microscopic ﬁndings are paracrystalline inclusions, crystals
consisting of mitochondrial creatinekinase.
Muscle enzymology is the next biochemical step in the
diagnosticwork-up.Activitiesofrespiratorychaincomplexes
can be assayed either in a group of 2 enzymes or as
single enzyme activities. Citratesynthase activity is usually
determined as a mitochondrial marker enzyme. We have
shown that the mitochondrial ATPsynthase (complex V) is
regulated both in rat heart [136] and in human skeletal
muscle [137] in response to energy demand. Active reg-
ulation of mitochondrial ATPsynthase requires an intact
inner mitochondrial membrane. We therefore advocate
measurement of respiratory chain enzymes in fresh muscle
preparations, as freezing leads to the disruption of the
inner mitochondrial membrane. Using this technique, we
have shown that secondary downregulation of ATPsynthase
(complex V) occurs in response to reduced electron ﬂow
across complexes I–IV [145]. Respiratory chain activity can
be inﬂuenced by a number of endogenous and exogenous
factors. For example, limb immobilisation has been shown
to lead to downregulation of mitochondrial pathways [146].
The heteroplasmic nature of most pathogenic mitochon-
drial DNA mutations makes genetic diagnosis diﬃcult [147].12 Journal of Biomedicine and Biotechnology
Genotype-phenotype correlation has been reported to be
poor [148]. By mutation analysis, mitochondrial depletion
syndromes may be identiﬁed which are characterized by
a reduction in mitochondrial DNA copy number [149].
Some of these show myopathy, together with other organ
manifestations.
In fresh, permeabilized muscle, respirometry can be
performed using a Clark-type electrode. By using diﬀerent
inhibitors of the respiratory chain-enzymes and uncouplers,
the rate-limiting step of respiration can be pinpointed [150,
151].
Using 31P MRS, reduction of the ratio of phosphocrea-
tine/inorganic phosphate can be detected, while ATP-levels
are normal, phosphocreatine depletion during exercise is
larger than normal, and the recovery rate of phosphocreatine
after exercise is typically reduced [27].
Mutation analysis may be performed. Both mutations
of the nuclear gene and the mitochondrial gene have been
reported (see above).
Treatment. Management and support in a multidisciplinary
team should be oﬀered to patients and their families.
Symptomatic treatment is important in order to prevent or
improve morbidity. Seizure-control by antiepileptic drugs
(valproic acid should be generally avoided, phenobarbital
should be avoided in complex I deﬁciency) and control
of diabetes by insulin are only few examples. A positive
energetic balance is desirable; “fast” carbohydrates should be
avoided as this may lead to excessive lactic acidosis.
Manysinglesubstanceshavebeentriedwiththerationale
of bypassing defective pathways, increasing residual enzyme
activities, or having an antioxidant function. For example,
succinatehasbeenusedtobypassdeﬁcientcomplexIactivity,
vitamin C and vitamin K may bypass deﬁcient complex
III, while vitamin E, alphalipoic acid, and coenzyme Q10
have been advocated as antioxidants. However, a recent
Cochrane review has stated that none of these as well as
other formsofcofactortherapy have been shown to be ofany
beneﬁt. Only coenzyme Q10 had a positive eﬀect in patients
presumably suﬀering from a disorder in coenzyme Q10
metabolism. Relatively high doses of 2.3mg/kg per day are
required.
KetogenicdiethasaremarkableeﬀectonCNS-symptoms
in PDH-deﬁciency but has also been tried in complex I
deﬁciency.
Certain drugs inhibiting mitochondrial protein syn-
thesis, like tetracyclines and chloramphenicol, should be
avoided.
5.Miscellaneous
Some disorders in muscle energy metabolism are very rare
and/or have mild symptoms. These are dealt with in this
section.
Recently, sudden cardiac death has been reported in
a child with muscle-speciﬁc glycogen synthase deﬁciency
[152]. In horses, but so far not in humans gain of function
mutations of glycogen synthase leading to myopathy has
been found [153].
Reduced activity of the phosphorylase kinase, which is
needed for glycogen breakdown, has been reported to lead to
mild myopathy [154, 155].
Inhibition of the glycolytic pathway at the level of
triosephosphate isomerase [156], phosphoglycerate kinase
[157], phosphoglycerate mutase [158], and enolase [159]h a s
been described to lead to myopathy with exercise-induced
muscle cramps and myoglobinuria.
6. SpecialProblems
Malignant hyperthermia is due to mutations in the ryan-
odinereceptorleadingtodefectsincalciumhomeostasistrig-
gered by certain anaesthetic compounds [160–162]. Some
neuromuscular diseases are known to be associated with
an increased risk of malignant hyperthermia if triggering
substances are used for anaesthesia.
Testing for malignant hyperthermia may be performed
by the caﬀeine halothane contracture test or by looking for
mutationsoftheryanodinereceptorgene.Asthegeneislarge
and many diﬀerent mutations are found, it is often safer,
faster, and less expensive to perform the caﬀeine halothane
contracture test. However, this involves doing a muscle
biopsy. It is often more practical to simply avoid anaesthetic
compoundsthattriggermalignanthyperthermia,ratherthan
doing the contracture test.
An increased risk for malignant hyperthermia has been
discussed in several disorders of energy metabolism like
CPT2 deﬁciency [163], respiratory chain defects [164, 165],
and McArdle disease [166]. Depolarizing drugs like suc-
cinylcholine for muscle relaxation may trigger malignant
hyperthermia. Though no ﬁrm correlation between inborn
errors of energy metabolism and malignant hyperthermia
has been established, it is probably wise to avoid triggering
substances in these patients.
Furthermore, inhalative anaesthetic agents have been
reported to interfere with NADH-linked respiratory chain
function [167]. Therefore, these compounds should be
avoided in patients with respiratory chain defects. Inhibition
of the respiratory chain could lead to free radical generation
which may mediate lipid peroxidation in cellular mem-
branes, thus inducing calcium eﬄux from cell organelles
which results in malignant hyperthermia [168].
Psychosocial problems may be another feature in
myopathies due to defects in energy metabolism, as more
and more patients with inborn errors of metabolism reach
adulthood. Inherited neuromuscular disorders aﬀect about
one in 3,500 children, with Duchenne muscular dystrophy
being the most common disease. To our knowledge, there
are no studies on quality of life, and psychosocial problems
in patients with myopathies based on compromised energy
metabolism.However,studiesonthespecialneeds,qualityof
life and psychosocial problems in boys/men with Duchenne
muscular dystrophy have been published [169, 170]. Obvi-
ously, inborn errors of energy metabolism are diﬀerent from
Duchenne muscular dystrophy where the physical handicap
isenormous.However,ithasbeenshownthatqualityoflifeis
notcorrelatedwithphysicalhandicapinDuchennemuscular
dystrophy. Therefore, problems may also be expected inJournal of Biomedicine and Biotechnology 13
Table 1
Disease Enzyme/Transporter Defect Main clinical features
GSD III (Cori-Forbes) Amylo-1,6 glucosidase
(debranching enzyme)
(distal) muscle weakness, cardiomyopathy, hepatomegaly, hypoglycaemia,
growth retardation;
osteoporosis, liver cirrhosis, hepatocellular carcinoma (later phase)
GSD V (Mc Ardle) Muscle phosphorylase Muscle pain (exercise-induced), myoglobinuria
GSD VII (Tarui) Muscle
phosphofructokinase Muscle pain (+ vomiting, nausea), anaemia
CPT2-deﬁciency Carnitine palmitoyl
transferase 2 Muscle weakness, cardiomyopathy, hepatomegaly, hypoglycaemia, seizures
MTP (Mitochondrial
trifunctional protein)
LCHAD, thiolase,
enoyl-CoA hydratase
Sudden death, “Reye-like” syndrome, respiratory dysfunction, capilliary
leak syndrome, myopathy, myoglobinuria, cardiomyopathy, peripheral
neuropathy, retinopathy
VLCAD-deﬁciency VLCAD Cardiomyopathy, muscle weakness, myoglobinuria, hypoglycaemia, liver
failure
MAD-deﬁciency (Glutaric
aciduria type II)
Electron transfer
ﬂavoprotein, electron
transfer ﬂavoprotein
dehydrogenase
Muscle weakness, cardiomyopathy, hypoglycaemia, respiratory
dysfunction, encephalopathy
CT-deﬁciency Carnitine transporter
SIDS, “Reye-like” syndrome, encephalopathy, muscle hypotonia, myalgia
(later), psychomotor delay, dilatative cardiomyopathy.
arrythmias, ventricular ﬁbrillations
Respiratory chain defects
Respiratory chain
complexes I–V (single or
combined)
Multisystem-disease (e.g., myopathy, cardiomyopathy, hepatopathy,
epilepsy, developmental delay, mental retardation, etc.)
metabolic myopathies. Further studies are required but may
be diﬃcult due to the rarity and high clinical variability of
metabolic myopathies.
7. Summary
Fatty acids are the main fuel for energy metabolism in heart
and skeletal muscle. In the initial anaerobic phase of skeletal
muscle contraction, muscular glycogen is used as a substrate.
There are many inborn errors of energy metabolism
leading to myopathies which have to be taken into account in
the diagnostic work-up. These concern fatty acid oxidation,
glycogenmetabolism,aswellasthe“ﬁnalcommonpathway”,
the mitochondrial respiratory chain. For most of the diﬀer-
ent metabolic disorders, speciﬁc therapeutic options exist.
Therefore, a metabolic work-up is mandatory in myopathies
(skeletal myopathy as well as cardiomyopathy) of unknown
origin. An overview, including the most common disorders,
is given in Table 1.
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